Literature DB >> 1851135

Inhibition of tumour necrosis factor alpha (TNF-alpha)-induced neutrophil respiratory burst by a TNF inhibitor.

A Ferrante1, B Hauptmann, P Seckinger, J M Dayer.   

Abstract

Tumour necrosis factor alpha (TNF-alpha) plays an important role in microbial defence and tissue damage by activating neutrophils. Therefore the ability of natural molecules to regulate the activity of TNF-alpha is likely to be of major importance in our understanding of the mechanisms of inflammation. We have examined the effects of a highly purified urine-derived TNF inhibitor (TNF inh) on the TNF-alpha-induced respiratory burst in human neutrophils. TNF-alpha inh-treated TNF-alpha was unable to stimulate a neutrophil lucigenin-dependent chemiluminescence response and superoxide formation. Treatment of TNF with the inhibitor also significantly reduced the priming ability of TNF-alpha for a response to the peptide f-met-leu-phe. These results show that the ability of TNF-alpha to induce a key neutrophil response is amenable to regulation by the TNF-alpha inh.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1851135      PMCID: PMC1384408     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  24 in total

Review 1.  Neutrophil activation by recombinant cytokines.

Authors:  M J Steinbeck; J A Roth
Journal:  Rev Infect Dis       Date:  1989 Jul-Aug

Review 2.  Tumour necrosis factor.

Authors:  M K Brenner
Journal:  Br J Haematol       Date:  1988-06       Impact factor: 6.998

3.  Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent.

Authors:  B M Babior; R S Kipnes; J T Curnutte
Journal:  J Clin Invest       Date:  1973-03       Impact factor: 14.808

4.  Effects of tumour necrosis factor alpha and interleukin-1 alpha and beta on human neutrophil migration, respiratory burst and degranulation.

Authors:  A Ferrante; M Nandoskar; A Walz; D H Goh; I C Kowanko
Journal:  Int Arch Allergy Appl Immunol       Date:  1988

5.  Two different cell types have different major receptors for human tumor necrosis factor (TNF alpha).

Authors:  H P Hohmann; R Remy; M Brockhaus; A P van Loon
Journal:  J Biol Chem       Date:  1989-09-05       Impact factor: 5.157

6.  Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor.

Authors:  P Seckinger; S Isaaz; J M Dayer
Journal:  J Biol Chem       Date:  1989-07-15       Impact factor: 5.157

7.  A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity.

Authors:  H Engelmann; D Aderka; M Rubinstein; D Rotman; D Wallach
Journal:  J Biol Chem       Date:  1989-07-15       Impact factor: 5.157

8.  A tumor necrosis factor binding protein is present in human biological fluids.

Authors:  C Peetre; H Thysell; A Grubb; I Olsson
Journal:  Eur J Haematol       Date:  1988-11       Impact factor: 2.997

Review 9.  The cytokine network.

Authors:  F R Balkwill; F Burke
Journal:  Immunol Today       Date:  1989-09

10.  Tumor necrosis factor alpha potentiates neutrophil antimicrobial activity: increased fungicidal activity against Torulopsis glabrata and Candida albicans and associated increases in oxygen radical production and lysosomal enzyme release.

Authors:  A Ferrante
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

View more
  6 in total

Review 1.  Etanercept: a review of its use in rheumatoid arthritis.

Authors:  B Jarvis; D Faulds
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

2.  Sputum tumour necrosis factor-alpha and leukotriene concentrations in cystic fibrosis.

Authors:  P Greally; M J Hussein; A J Cook; A P Sampson; P J Piper; J F Price
Journal:  Arch Dis Child       Date:  1993-03       Impact factor: 3.791

3.  Differential effects of small tumour necrosis factor-alpha peptides on tumour cell cytotoxicity, neutrophil activation and endothelial cell procoagulant activity.

Authors:  D A Rathjen; A Ferrante; R Aston
Journal:  Immunology       Date:  1993-10       Impact factor: 7.397

4.  Thalidomide in the Treatment of Sweet's Syndrome and Eosinophilic Folliculitis Associated With Immune Reconstitution Inflammatory Syndrome.

Authors:  Rong-Jing Dong; Shi-Zhen Huang; Pratishtha Upadhyay; Samip Shrestha; Ya-Jie Zhai; Yu-Ye Li
Journal:  Front Med (Lausanne)       Date:  2020-01-21

5.  The effect of tumour necrosis factor-alpha (TNF-alpha) muteins on human neutrophils in vitro.

Authors:  H Tchorzewski; K Zeman; J Kantorski; E Paleolog; M Kahan; M Feldmann; M Kwinkowski; P Guga; B Szymanska; P Parniewski; A Wilk; J Jarosz
Journal:  Mediators Inflamm       Date:  1993       Impact factor: 4.711

6.  Spleen Tyrosine Kinase Is a Critical Regulator of Neutrophil Responses to Candida Species.

Authors:  Paige E Negoro; Shuying Xu; Zeina Dagher; Alex Hopke; Jennifer L Reedy; Michael B Feldman; Nida S Khan; Adam L Viens; Natalie J Alexander; Natalie J Atallah; Allison K Scherer; Richard A Dutko; Jane Jeffery; John F Kernien; J Scott Fites; Jeniel E Nett; Bruce S Klein; Jatin M Vyas; Daniel Irimia; David B Sykes; Michael K Mansour
Journal:  mBio       Date:  2020-05-12       Impact factor: 7.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.